Anti-CTLA-4 [CP-675,206 (Tremelimumab, 11.2.1)]

Catalogue Number: AB02327-3.3-ABA

Manufacturer:	Vector Laboratories, Inc (ABA)
Type:	Recombinant Monoclonal
Alias:	CD152; CTLA4; Cytotoxic T-lymphocyte protein; Cytotoxic T-lymphocyte-associated antigen 4
Shipping Condition:	Blue Ice
Unit(s):	200 ug
Host name:	Mouse
Clone:	CP-675,206 (Tremelimumab, 11.2.1)
Isotype:	IgG2b
Immunogen:	The original antibody was generated by immunizing XenoMouse® mice with cells expressing human CTLA-4 recombinantly.
Application:	ELISA, FC, Blk

Overview
Datasheets

Additional Text

Uniprot ID

P16410

Gene ID

1493

Gene Name

CTLA4

Purification

Purified

Antibody Clonality

Recombinant Monoclonal

Storage Note

Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.

Application Notes

Formerly known as ticilimumab, this Antibody is a fully human anti-huCTLA4 antagonist. It binds human and cycynomolgus monkey CTLA4 in flow cytometric analysis. It binds immobilized human and monkey CTLA4-Ig with average affinities of 0.28 and 0.98 nM, respectively. It is also reported that this antibody does not induce release of cytokines and also does not bind to human leukocyte Fc receptors. It blocks binding of human CTLA4-Ig to immobilized B7.1 and B7.2 with average IC50 values of 0.65 and 0.50 nM in competition binding studies. It was reported to enhance IL-2 and interferon-gamma production in human T cell blasts stimulated with B7-positive Raji cells and also enhanced IL-2 production in a concentration dependent manner in human and cynomolgus monkey whole blood (WB) and peripheral blood mononuclear cells (PBMC) stimulated with staphylococcal enterotoxin A (SEA) superantigen (Hansen et al, 2004). Phase I clinical trial with patients having advanced solid malignancies revealed that this antibody was safe and well tolerated and the related autoimmunity caused is reversible (Camacho et al., 2004). Phase 1 clinical trials in patients with advanced melanoma suggested that this antibody can be safely administered in a recommended dosage of 10 mg/kg every month and has antitumor activity in melanoma at monthly doses consistent with prolonged CTLA4 blockade (Ribas et al., 2005). It is also reported that therapy with this antibody reduces regulatory T cells and IL-10 production in patients with advanced malignant melanoma (Reuben et al., 2005).

Short Description

This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG2 format, for improved compatibility with existing reagents, assays and techniques.

AB02327-3.3 Datasheet

Price

£390.00

-

Quantity
Unit Size

Find out about delivery